Quick Answer
Emmaus Life Sciences, Inc. reported Net Income Loss of -$7.49 million for the year ending 2025.
- Emmaus Life Sciences, Inc. showed a decrease of -16.1% in Net Income Loss from 2024 to 2025.
- This data is from Emmaus Life Sciences, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2011 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2013: -$1.33 million | Q4 2013: $135.1 thousand | Q1 2014: -$942.0 thousand | Q2 2014: -$1.02 million | Q4 2014: -$874.6 thousand | Q1 2015: -$696.3 thousand | Q2 2015: -$536.8 thousand | Q4 2015: -$3.45 million | Q1 2016: -$142.7 thousand | Q2 2016: -$1.35 million | Q4 2016: -$1.44 million | Q1 2017: -$1.45 million | Q2 2017: -$1.57 million | Q4 2017: -$2.77 million | Q1 2018: -$2.59 million | Q2 2018: -$2.61 million | Q3 2018: $14.57 million | Q4 2018: -$2.38 million | Q1 2019: -$17.41 million | Q2 2019: -$17.60 million | Q3 2019: -$18.39 million | Q1 2020: $5.51 million | Q2 2020: -$9.47 million | Q3 2020: $5.59 million | Q1 2021: -$8.42 million | Q2 2021: $2.49 million | Q3 2021: -$3.15 million | Q1 2022: -$1.54 million | Q2 2022: -$8.89 million | Q3 2022: -$391.0 thousand | Q1 2023: -$3.45 million | Q2 2023: -$1.56 million | Q3 2023: $67.0 thousand | Q1 2024: -$4.35 million | Q2 2024: -$2.18 million | Q3 2024: $1.83 million | Q1 2025: -$2.33 million | Q2 2025: -$1.14 million | Q3 2025: -$2.08 million.
- Over the full 16 years of available data (2011 to 2025), Emmaus Life Sciences, Inc.'s Net Income Loss has grown by 15.5%.
- Historical annual values: Fiscal year 2025: -$7.49 million | Fiscal year 2024: -$6.45 million | Fiscal year 2023: -$3.73 million | Fiscal year 2022: -$10.63 million | Fiscal year 2021: -$15.95 million | Fiscal year 2020: $1.35 million | Fiscal year 2019: -$54.84 million | Fiscal year 2018: -$72.59 million | Fiscal year 2018: -$9.60 million | Fiscal year 2017: -$7.11 million | Fiscal year 2016: -$5.94 million | Fiscal year 2015: -$3.38 million | Fiscal year 2014: -$2.66 million | Fiscal year 2013: -$10.91 million | Fiscal year 2012: -$3.41 million | Fiscal year 2011: -$8.87 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: